Physician profile
Laurel Carter
NPI 1083118855
$1,892.33
in general payments reported to CMS, 2019-2025
24 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $410 · 2023: $202 · 2024: $863 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.82 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $683.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biotronik Nro, INC. | $208.82 | 2024-2025 | Prospera |
| Lilly USA, LLC | $202.43 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.16 | 2022-2025 | Jardiance |
| Abbvie INC. | $80.15 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Amgen INC. | $78.01 | 2023-2024 | Evenity, Otezla, Prolia |
| Pfizer INC. | $54.68 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $53.92 | 2024 | |
| Daiichi Sankyo INC. | $52.23 | 2024-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $44.77 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Phadia US INC. | $36.64 | 2022-2024 | Immunocap |
| Grifols USA, LLC | $33.00 | 2024-2025 | Prolastin-C Liquid |
| Abiomed | $30.51 | 2025 | |
| Edwards Lifesciences Corporation | $29.91 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Seqirus USA INC | $25.24 | 2025 | Flucelvax, Fluad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $24.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| Eisai INC. | $18.92 | 2024 | |
| Insulet Corporation | $17.14 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $16.21 | 2024 | Shingrix, Arexvy |
| Echosens North America, INC. | $14.92 | 2025 | Fibroscan |
| Exact Sciences Corporation | $13.98 | 2025 | The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $12.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.